Page 6 - Global Phase News Today

DGAP-News: Formycon AG / Key word(s): Study results/Study Formycons Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficac...

DGAP-News: Formycon AG / Key word(s): Study results/StudyFormycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara®* in Phase III Study 16.08.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Press Release // August 16, 202...

16.08.2022 - DGAP-News: Formycon AG / Key word(s): Study results/Study Formycons Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara* in Phase III Study 16.08.2022 / 07:30 CET/CEST The issuer is solely responsible ... Seite 1

Press release content from Business Wire. The AP news staff was not involved in its creation.

Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis’ eplontersen met its co-primary endpoints in a planned interim analysis at 35 weeks. In the trial, eplontersen reached a ...

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical

Affibody, ACELYRIN, and Inmagene Bio Announce Positive Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic ArthritisSolna, Sweden, Los...

SV Health Investors Joins Prilenia Series B as the Company Prepares for ALS and HD Data Readouts in the Next 12 Months - read this article along with other careers information, tips and advice on BioSpace

/PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced four presentations on amyotrophic lateral sclerosis (ALS) will be shared as part...

Investegate announcements from Hutchmed China Ltd, HUTCHMED Receives $15m Milestone from AstraZeneca